Sector News

Largest Ablynx investor would consider improved Novo Nordisk bid

January 19, 2018
Life sciences

The largest shareholder in Belgian biotech group Ablynx regards the 2.6 billion euro ($3.2 billion) offer made by Denmark’s Novo Nordisk as too low but would be willing to consider a higher figure.

Van Herk Investments, which owns about 10.2 percent of Ablynx, said it agreed with the Belgian company’s board that the offer undervalued Ablynx’s caplacizumab treatment for rare blood disorders, its pipeline, technology, people and know-how.

The vehicle of Dutch investor Aat van Herk said in a statement that it was willing to consider an offer for Ablynx that properly reflects the value of the company.

If Van Herk Investments considers a potential offer properly reflects the value of Ablynx its intention is to encourage the Ablynx board to enter open dialogue with the bidder, it said.

Analysts have predicted that Novo Nordisk might face counter-bidders and would need to raise its offer.

Van Herk had not spoken to Novo Nordisk but is willing to talk even without an improved offer, a spokesman for Van Herk said. He declined to specify what would constitute a reasonable price.

“The company is on the brink of being a commercial-stage biotech company. There are not a lot of these companies in Europe, so it is a very big achievement,” he said.

Novo Nordisk had been very open about its interest in Ablynx’s lead product, he said, but it was important that other programmes continued. The Danish bidder has said it would maintain Ablynx’s strong research and development base in the Belgian city of Ghent.

Novo Nordisk is offering up to 30.50 euros per Ablynx share.

The shares were trading at 34.66 euros on Thursday, giving it a market capitalisation of 2.95 billion euros. ($1 = 0.8203 euros)

By Philip Blenkinsop

Source: Reuters

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend